Middle East and Africa Skin Cancer Diagnostics Market

The Middle East & Africa skin cancer diagnostics market is expected to reach US$ 214.3 million by 2028 from US$ 160.5 million in 2021; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028.

Technologically advanced dermatoscopes aid in better visualizing skin cancers and has improved diagnostics sensitivity by 10–30%. Similarly, developments in AI technology enabled its application in the early detection of skin cancer. In February 2022, researchers at Fraunhofer Center for Assistive Information and Communication Solutions (AICOS) in Porto and Lisbon announced their Derm.AI software that offers a smooth primary assessment of skin lesions on the skin surface that look potentially dangerous. It combines the photos of skin lesions taken from smartphones with image analysis software and AI. The software is likely to help dermatologists to access and analyze cases and risks of skin cancer. At present, the researchers of the Derm.AI solution aim to improve the existing teledermatology processes in the Portuguese National Health System. They are also working on developing solutions for analyzing the results from mobile apps, further enhancing the deep-learning model of Derm.AI. The software was developed in partnership with shared services of the Ministry of Health and clinical partners, namely IPO Coimbra, CHUP, and ULS Guarda.

With the new features and technologies, vendors attract new customers and expand their footprints in emerging markets. This factor is driving the growth of the Middle East & Africa skin cancer diagnostics market at a promising CAGR.

Middle East & Africa Skin Cancer Diagnostics Market Revenue And Forecast To 2028 (US$ Million)

The skin cancer diagnostics market is segmented into type and screening type. Based on type, the market is segmented into melanoma and non-melanoma. Based on screening type, the market is segmented into skin biopsy, dermatoscopy, lymph node biopsy, imaging tests, and blood tests. Based on country, the market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa.

AMLo Biosciences Limited; DermLite LLC; bioMerieux SA; Hoffmann-La Roche Ltd.; and Michelson Diagnostics Ltd. are among the leading companies in the Middle East & Africa skin cancer diagnostics market.      

Middle East and Africa Skin Cancer Diagnostics Strategic Insights

Strategic insights for the Middle East and Africa Skin Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East and Africa Skin Cancer Diagnostics Report Scope

Middle East and Africa Skin Cancer Diagnostics Regional Insights

The geographic scope of the Middle East and Africa Skin Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.